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Genetic polymorphisms in thepromoter region of the tumour necrosis factor-a (TNF-a) gene are involved in
the regulation of the expression levels of its cytokine. Besides, these polymorphisms have been associated
with the clinical behaviour of cancer. We investigated the 308 promoter region polymorphisms of the
TNF-a gene and its association with the clinicopathological factors of a head and neck squamous cell carci-
noma (HNSCC) sample. Furthermore, we analysed the impact of all the variables on the overall survival of
patients. A sample of HNSCC (n = 89) was evaluated. Clinicopathological factors and overall survival data
were gathered. The TNF-a gene was analysed by using polymerase chain reaction–restriction fragment
length polymorphism (PCR–RFLP). Data analyses were performed by using bivariate and multivariate
statistical tests. Signiﬁcance was set at p < 0.05. HNSCC subjects carrying the A allele (GA/AA) exhibited
associations with poor performance status (OR = 2.82, p = 0.039), lesions located on posterior areas
(OR = 4.02, p = 0.002), and large-size tumours (OR = 2.91, p = 0.015). Subjects carrying only AA genotype
exhibited association with poor performance status (OR = 6.667, p = 0.007). A worse overall survival was
noted in subjects with large tumours (OR = 4.87, p = 0.005) and locoregional metastatic disease
(OR = 2.50,p = 0.018).Ourdata suggests that thepresence of theAallele/AAhaplotype inHNSCC individuals
might contribute to the higher clinical aggressiveness of malignant disease.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.Introduction
Head and neck cancer represents a broad term that encompasses
a group of human malignancies that arise in the epithelial lining of
the upper aerodigestive tract mucosa. It represents the sixth most
common type of human cancer, and it is responsible for high death
rates worldwide every year.1–7 About 90% of the head and neck can-
cers are diagnosed as squamous cell carcinoma (SCC).8 A plethora of
socio-demographical, economic, and cultural factors associated
with a background of genetic disturbances are pivotal for the inci-
dence and development of head and neck SCC (HNSCC).8–10
The rate of tumour development is regulated by a delicate
balance between pro- and anti-tumourigenic activities promoted
by the neoplastic cells themselves as well as other cells located ins-graduação em Ciências da
iversitário Clemente de Faria,
ula Mangabeira, 562 Bairro
G, Brazil. Tel.: +55 21 38
e Paula).
er OA license.the surrounding microenvironment. From this cellular variety are
produced several cytokines that modulate the local/systemic im-
mune response that inhibits or stimulates the development of can-
cer.11,12 The human tumour necrosis factor-alpha (TNF-a) gene is
located in the chromosome six region (p21.231), within the class
III region of the major histocompatibility complex.13,14 TNF-a has
multiplewell-recognised biological activities inmany physiological
processes such as cell differentiation, proliferation, apoptosis, en-
ergymetabolism, and immune status.13,15 Froma pathological point
of view, TNF-a has been noted as an important regulator of some
inﬂammatory diseases and malignancies.13,14,16 In cancer studies,
it has been observed that TNF-amight act in paradoxical roles. Ther-
apeutically, a high local dose of TNF-a seems to have powerful anti-
neoplastic actions.17 However, when chronically produced, this
cytokine seems to act as an endogenous regulator that promotes
the tissue remodelling for tumour growth and spread.17–20
The TNF-a gene exhibits an important functional polymorphism
located at position 308 in its promoter region. This genetic varia-
tion results in two allelic forms, in which the presence of guanine
(G) deﬁnes the common variant, but adenine (A) deﬁnes the less
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found in regions that regulate transcription or post-transcriptional
events and seem to be functionally signiﬁcant.21–23 Analysis of
TNF-a polymorphisms have shown evidence of this cytokine as a
susceptibility and prognosis factor in some types of human can-
cers.24–27 The 308 TNF-a promoter region polymorphism has
exhibited an association with the susceptibility to head and neck
carcinoma.28–31 However, the impact of this polymorphism with
the clinicopathological factors and prognosis for HNSCC has not
been studied yet.
The aim of the present study was to investigate the association
between 308 TNF-a promoter region polymorphisms in a sample
of HNSCC, in accordance with clinicopathological factors. In addi-
tion, we also analysed the impact of all these variables on the over-
all survival of the individuals.Material and methods
Ethical approval for this study was obtained from the relevant
local ethics committees (Unimontes/CEP-1114/2008).
Tissue specimens and patients
This retrospective study was performed on archived tissue
blocks from surgically resected HNSCC primary specimens
(n = 89). Socio-demographical, clinicopathological, overall survival
data, and samples were obtained from the Health Centre for Oncol-
ogy at Montes Claros city, Minas Gerais, Brazil. All diagnoses of
malignant disease were conﬁrmed by histopathological analysis.
Anatomical site and clinicopathological staging
All HNSCC patients were classiﬁed according to the IUAC-TNM
Classiﬁcation of Malignant Tumours on the basis of the primary
site, as described in the ICD for oncology.32 The anatomical sites re-
viewed in this study included (1) oral cavity and perioral region
(all: 40 patients/44.9% – ﬂoor of the mouth: 10/25%, tongue: 15/
37.5%, retromolar trigonum: 5/12.5%, lip: hard/soft palate: 4/10%,
gum: 2/5%, lower lip mucosa: 4/10%), (2) oropharynx (n = 25/
28.2%), (3) hypopharynx (n = 6/6.7%), and larynx (n = 18/20.2%).
The lesions located in the oral cavity were considered as the ante-
rior group and those located in the oropharynx–hypopharynx–lar-
ynx as the posterior group for characterisation of the anatomical
site variable. According to the TNM staging, HNSCC patients were
staged as I (n = 3/3.4%), II (n = 22/24.7%), III (n = 31/34.8%), and IV
(n = 33/37.1%). Morphological grading of the HNSCC group was
on the basis of the WHO criteria.33Figure 1 Polyacrylamide gel electrophoresis for detection of (308 G/A) TNF-a polymorph
2); genotype AA = 107 bp (lane 7); genotype G/A = 107 + 87 bp (lanes 3 and 4); genotypEvaluation of the performance status
The Eastern Cooperative Oncology Group-Performance Status
(ECOG-PS) scale was used to evaluate the functional status of the
HNSCC patients. The ECOG-PS scale is used to measure physical
functioning as well as medical care requirements in patients with
cancer.34,35 The ECOG-PS scale categorises cancer patients into ﬁve
groups: 0, normal activity; 1, strenuous activity restricted; 2, up
and about for >50% of the waking hours; 3, conﬁned to bed/chair
for >50% of the waking hours; 4, 100% bedridden; and 5, dead. This
validated and reliable instrument has offered additional support as
a prognostic indicator.36,37 This evaluation was rated by only one
head and neck surgeon at the time of diagnosis. HNSCC samples
were divided into two groups according to the ECOG-PS evaluation
(0–1: good and 2–4: poor).Genotyping for 308 TNF-a promoter region single nucleotide
polymorphisms
DNA was isolated from 10 tissue sections (thickness: 10-lm)
from each tissue block of the HNSCC specimens by using the
DNeasy Tissue Kit (Qiagen, Chatsworth, California, USA) in accor-
dance with the manufacturer’s protocol. The allelic and genotypic
polymorphisms of the 308 TNF-a promoter region were evalu-
ated according to previously described methods.38 Brieﬂy, poly-
merase chain reaction–restriction fragment length polymorphism
(PCR–RFLP) used a forward primer (50-TCCTCCCTGCTCCGATTCCG-
30) and a reverse primer (50-AGGCAATAGGTTTTGAGGGCCAT-30).
The PCR mixture consisted of about 0.2 lg of genomic DNA,
0.2 mM dNTPs, 0.3 lM of each primer, 1.5 mMMgCl2, 1Taq poly-
merase buffer, and 0.5 U of Taq DNA polymerase (PhoneutraBio-
tecnologia, BH, Brazil); the ﬁnal volume was 50 lL. The PCR–
RFLP products were separated from the unincorporated primers
and dNTPs by using a commercial kit (PCRclean) and were then
subjected to NcoI enzyme digestion (37 C/12 h). The ampliﬁcation
conditions were as follows: 95 C for 5 min; 35 cycles at 95 C for
30 s, 58 C for 30 s, and 72 C for 45 s, and the ﬁnal extension step
at 72 C for 10 min. The ampliﬁcation yielded a fragment of 107 bp,
which was digested overnight with 10 U of the restriction enzyme
NcoI at 37 C. After the complete digestion, the resulting DNA frag-
ments were separated by using 6.5% polyacrylamide gel electro-
phoresis (PAGE) on a 1% agarose gel, stained with silver, and
photographed. The allele G was cleaved by the enzyme into two
fragments, one of 87 bp and another of 20 bp (GG). The haplotype
GA is composed of three fragments: 107, 87, and 20 bp. The A allele
was not cleaved by the enzyme and therefore, generated one frag-
ment of 107 bp (AA) (Fig. 1).ism. Base pair ladder (100 bp) (lane 1); PCR product without digestion = 107 bp (lane
e GG = 87 bp (lanes 5 and 6).
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The Hardy–Weinberg equilibrium was assessed by using a
goodness-of-ﬁt chi-square (v2)-test for the biallelic biomarker.
The following variables were included as covariates: ECOG-PS (0–
1 vs. 2–4 groups), anatomical site (anterior vs. posterior), tumour
size (small lesions-T1/T2 vs. large lesions-T3/T4), cervical metasta-
sis (absent: N0 vs. present: N1/N2/N3), and the WHO morpholog-
ical grading (I–II vs. III grades). In order to evaluate the
association between the covariates and the molecular biomarker
(TNF-a-dependent variable), bivariate analyses were performed
by using the Mantel–Haenszel Pearson v2 test.
Concerning to overall survival analysis, all deaths occurred by
HNSCC. Patients who died without evidence of recurrence/metas-
tasis were considered censored by the last clinical evaluation.
Five-year survival rates were estimated and survival curves were
plotted according to the Kaplan–Meier test. Differences were
tested by the log rank test. Multivariate survival analyses were
accomplished using Cox’s proportional hazards regression model
to access independent prognostic factors. Only covariates with
p < 0.02 were considered one at a time for entry into the multivar-
iate models by using a backward step-wise procedure. The ﬁnal
model represented the most restricted subset of variables having
prognostic signiﬁcance. Associations were expressed as odds ratio
(OR) values with the corresponding 95% conﬁdence interval
(CI95%). Statistical signiﬁcance was set at p < 0.05. All statistical
analyses were performed by using the SPSS 13.0 package (SPSS
Inc., Chicago, USA).
Results
The socio-demographical, clinicopathological, and molecular
characteristics of the HNSCC sample
Distribution of the socio-demographical, clinicopathological,
survival data, and alleles and haplotypes of 308 TNF-a is exhib-
ited in Table 1. The male-to-female ratio in the sample was 9:1.
The mean age was 60.34 (±12.56 years), and median age was
61 years (range: from 33 to 91 years).Table 1
Baseline characteristics of the HNSCC patients investigated in this study.
Variables n % Variables n %
Age Gender
Young 16 18 Female 9 10.1
Older 73 82 Male 80 89.9
Tobacoo habit Alcohol habit
Present 25 28.1 Present 43 48.3
Absent 64 71.9 Absent 46 51.7
Cancer family Weight loss
Present 52 58.4 Absent 77 86.5
Absent 37 41.6 Present 12 13.5
ECOG Anatomical site
Good 65 73.0 Anterior 40 44.9
Poor 24 27.0 Posterior 49 55.1
Tumour size Cervical metastasis
T1/T2 34 38.2 Absent 44 49.4
T3/T4 55 61.8 Present 45 50.6
Overall survival WHO grade
6700 days 45 50.6 I 22 24.7
>700 days 44 49.4 II 38 42.7
III 29 32.6
(308G)TNF-a genotype Carrier allele A
GG 46 51.7 Absent (GG) 46 51.7
GA 31 34.8 Present (GA/AA) 43 48.3
AA 12 13.5Association of HNSCC with allelic and genotypic 308 TNF-a
polymorphisms
The 308 TNF-a haplotype frequencies in this HNSCC sample
loci exhibited an insigniﬁcant v2-value in the Hardy–Weinberg test
(v2 = 3.024, p = 0.082). Table 2 shows bivariate comparisons be-
tween the clinicopathological independent variables and allelic
and genotypic (308A) TNF-a polymorphisms. Our results showed
that poor ECOG-PS (OR = 2.82, p = 0.039), lesions located on the
posterior sites of the head and neck (OR = 4.02, p = 0.002), and
large-size tumours (OR = 2.91, p = 0.015) exhibited a signiﬁcant
association with HNSCC individuals carrying 1 or 2 TNF-a A alleles
(GA/AA). Notably, HNSCC individuals carrying the AA haplotype
exclusively showed a signiﬁcant association with poor ECOG-PS
(OR = 6.667, p = 0.007) (Table 3).
Prognostic signiﬁcance
The HNSCC patients were followed up for a time that ranged
from 2 to 3835 days (mean: 982.1 ± 851.9 days and median:
669 days). At the time of the last evaluation (1826 days–5 years),
it was noted that 45 patients (50.6%) were alive and 44 patients
(49.4%) died because of head and neck carcinoma. A total of 25
(28.1%) patients were censored during the follow-up after a time
period ranging from 42 to 1765 days (mean: 939.7 days: ±550.1).
In the bivariate analysis, covariates such as worse ECOG-PS
(p = 0.04), large-size tumour (p = 0.000), metastatic disease
(p = 0.000), and GA genotype (p = 0.041) exhibited a signiﬁcant
association with the overall survival (Fig. 2). Subsequently, using
Cox’s regression multivariate models, signiﬁcant differences were
noted when we tested the relationship between covariates such
as large-size tumour (OR = 4.87, p = 0.005) and presence of cervical
metastasis (OR = 2.50, p = 0.018) with the overall survival. Our re-
sults did not show a signiﬁcant association between the 308
TNF-a polymorphisms and overall survival (data not shown).Discussion
A background of genetic and environmental factors modulates
the biological behaviour of cancer. Among them, DNA polymor-
phisms in low penetrance genes and their cooperative interaction
with related exogenous factors have been appointed as the pivotal
modulators of the biological behaviour of malignancy.39,40 In theTable 2
Analysis between the socio-demographical and clinicopathologic covariates according
to the allelic (G308)TNF-a polymorphisms in the HNSCC sample.
Variables (308)TNF-a allelic frequencies
G A OR (CI95%) p Value
ECOG-PS
Good 38 (58.5%) 27 (41.5%) 2.82 (1.06–7.51) 0.039*
Poor 8 (33.3%) 16 (66.7%)
Anatomical site
Anterior 28 (70%) 12 (30%) 4.02 (1.65–9.80) 0.002*
Posterior 18 (36.7%) 31 (63.3%)
Tumour size
T1/T2 23 (67.6%) 11 (32.4%) 2.91 (1.19–7.22) 0.015*
T3/T4 23 (48.1%) 32 (58.2%)
Cervical metastasis
Absent 22 (50%) 22 (50%) 0.88 (0.38–2.01) 0.459
Present 24 (53.3%) 31 (46.7%)
WHO grade
I–II 34 (56.7%) 26 (43.3%) 1.85 (0.76–4.55) 0.130
III 12 (41.4%) 17 (58.6%)
* Values bearing asterisks are statistically signiﬁcant using the Mantel–Haenszel
Pearson v2 test.
Table 3
Analysis between the clinicopathological covariates according to the haplotype (G308)TNF-a polymorphisms in the HNSCC sample.
Variables (n/%) (308GA) TNF-a genotype frequencies
GG GA AA p Value
ECOG-PS
Good 38 (58.5%) 22 (33.8%) 5 (7.7%) 0.231
Poor 8 (33.3%) 9 (37.5%) 7 (29.2%) 0.007*
OR (CI95%) Referent 1.942 (0.173–5.780) 6.667 (0.04–26.32)
Anatomical site
Anterior 28 (70%) 7 (17.5%) 5 (12.5%) 0.356
Posterior 18 (36.7%) 24 (49%) 7 (14.3%) 0.238
OR (CI95%) Referent 5.35 (0.07–14.93) 2.18 (0.13–7.94)
Tumour size
T1/T2 23 (67.6%) 9 (26.5%) 2 (5.9%) 0.546
T3/T4 23 (48.1%) 22 (40%) 10 (18.2%) 0.052
OR (CI95%) Referent 2.45 (0.16–6.41) 5.00 (0.04–25.64)
Cervical metastasis
Absent 22 (50%) 14 (31.8%) 8 (18.2%) 0.818
Present 24 (53.3%) 17 (37.8%) 4 (8.9%) 0.251
OR (CI95%) Referent 1.11 (0.36–2.78) 0.46 (0.58–1.74)
WHO grade
I-II 34(56.7%) 17 (28.3%) 9 (15%) 0.086
III 12(51.7%) 14 (34.8%) 3 (13.5%) 0.939
OR (CI95%) Referent 2.33 (0.89–6.14) 0.94 (0.25–4.08)
* Values bearing asterisks are statistically signiﬁcant using the Mantel–Haenszel Pearson v2 test.
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A alleles showed association with clinical factors of high severity
such as large-size tumour, poor performance status of patients,
and occurrence of carcinoma on the posterior sites of the upper
aerodigestive tract.
Some in vitro and in vivo studies have shown that TNF-a might
actively contribute to the tissue remodelling and stromal develop-
ment necessary for tumour growth and spread.18,19,41 When pro-
duced chronically by tumour–tumour, immune, and resident
stromal cells, the TNF-a cytokine may act as an endogenous tu-
mour growth factor by promoting cancer-cell proliferation through
the activation of the nuclear factor kappa-b, PI3K/PKB (Akt), and
the mitogen-activated protein kinase-dependent pathways.42 Be-
sides, TNF-a also promotes tumour growth by stimulating endo-
thelial-cell differentiation and extracellular matrix production or
stimulating other inﬁltrating cells to produce angiogenic fac-
tors.43,44 According to our ﬁndings, it is possible that HNSCC indi-
viduals carrying the high producing A allele might present local
tissue conditions on the upper aerodigestive tract mucosa that fa-
vours the growth and development of SCC.
Our ﬁndings also exhibited signiﬁcant associations between
both the high producing A allele and the AA haplotype with worse
functional status in the HNSCC patients. Interesting in vitro and
in vivo studies have shown evidence of the contribution of the
TNF-a cytokine in malnutrition, weight loss, and cachexia distur-
bances in cancer patients.45–50 It must be emphasised that there
are limits for the characterisation of each one of these distur-
bances. While the evaluation of functional status performance is
essentially clinical, the disturbances of weight loss and cachexia
in cancer patients involve several, but still imprecise, energetic
and metabolic abnormalities.51 However, it is rather reasonable
to make certain inferences about the possible participation of
TNF-a in the performance status of the HNSCC sample in this
study. The persistent inﬂammatory response of the host, in con-
junction with appropriate production and release of cytokines such
as TNF-a, IL-1, and IL-6 is central to weight loss and cachexia in
cancer patients.51,52 TNF-a expression might be induced by pro-
cachectic factors like proteolysis-inducing factor and activator pro-
tein-1, which are the transcription factors involved in promoting
cachexia.19,53,54 After its expression, TNF-a participates in the
recruitment and degranulation of inﬂammatory cells that contrib-ute actively to tissue degradation, especially acting on protein sub-
strates, as noted frequently in the degradation of skeletal muscle
tissue in cancer patients.55–59
Approximately 25% of the HNSCC patients worldwide are asso-
ciated with high-risk human papillomaviruses (HPV)-16, 18, 31,
33, and 35.60 Interesting, high-risk HPV-positive infection (60–
70%) has been associated with SCC located in the oropharyngeal
and larynx regions.60–65 In our study, our HNSCC samples were
classiﬁed as the posterior group; about 88% of the lesions were lo-
cated in the oropharyngeal and larynx and exhibited a higher OR
with individuals that presented the A allele and AA haplotype. It
has been shown that HPV-transformed cells escape the host im-
mune-cell control during carcinogenesis and become resistant to
TNF-a mediated cytotoxicity. Additionally, the cytotoxicity pro-
moted by TNF-a apparently stimulates the proliferation of HPV-
immortalised epithelial cells.66 We hypothesise that a possibly
high expression of TNF-a, characterised by the presence of the high
producer A allele, in association with the presence of HPV infec-
tion, could favour an immunosuppressive scenario to the HNSCC
development in this anatomical site. However, that hypothesis
needs to be conﬁrmed in further studies.
HNSCC patients frequently exhibit a worse overall survival with
about just 60% of all patients reaching the 5-year survival.2–6 We
found that HNSCC individuals with large-size tumours and with
metastatic disease presented worse overall survival. These ﬁndings
are consistent with fundamental concepts that establish the contri-
bution of tumour size and lymph-node metastasis factors to the
HNSCC outcome. A few studies showed that the GA haplotype is
strongly associated with the susceptibility of some types of human
cancer67–69, including oral SCC.28 Additionally, the AA/GA haplo-
types of the TNF-a polymorphisms are generally associated with
poor prognosis in patients with lymphoma.70,71 Although, by using
bivariate tests (p = 0.041), we observed that the GA haplotype
exhibited association with worse overall survival in our sample,
neither allelic nor 308 TNF-a haplotypes had an impact on the
overall survival using multivariate statistical tests. Future studies
are needed to foster a better understanding about the participation
of TNF-a in the outcome of patients with HNSCC.
In conclusion, this study identiﬁed that HNSCC individuals car-
rying the high producer A allele and the high risk AA haplotype for
the308 TNF-a gene might exhibit local/systemic biological condi-
Figure 2 Overall survival analysis in HNSCC patients after 1826 days according to TNF-a allele and haplotype frequencies, tumour size, and cervical metastasis parameters.
The difference between groups was evaluated by the log-rank test and the differences were statistically signiﬁcant.
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performance status, lesions located on the posterior sites of the
head and neck, and large-size tumours were associated with
HNSCC individuals carrying 1 or 2 TNF-a A alleles. Neither allelic
nor genotypic TNF-a polymorphisms showed impact on the overall
survival of HNSCC patients in this study.Conﬂict of interest statement
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